Israel - hebreu - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

Israel - hebreu - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

Israel - hebreu - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib - טבליות מצופות פילם - erlotinib 100 mg - erlotinib

Israel - hebreu - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib - טבליות מצופות פילם - erlotinib 100 mg - erlotinib

Israel - hebreu - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib - טבליות מצופות פילם - erlotinib 150 mg - erlotinib

Israel - hebreu - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib - טבליות מצופות פילם - erlotinib 150 mg - erlotinib

Israel - anglès - Ministry of Health

roche pharmaceuticals (israel) ltd - obinutuzumab - concentrate for solution for infusion - obinutuzumab 1000 mg / 40 ml - obinutuzumab - chronic lymphocytic leukaemia (cll)gazyva, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll).follicular lymphoma (fl )gazyva, in combination with bendamustine followed by gazyva monotherapy, is indicated for the treatment of patients with follicular lymphoma (fl) who did not respond or who progressed during or up to 6 months after treatment with a rituximab-containing regimen.gazyva in combination with chemotherapy, followed by gazyva maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

Israel - anglès - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab emtansine - powder for concentrate for solution for infusion - trastuzumab emtansine 20 mg/ml - trastuzumab - "early breast cancer (ebc):kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with her2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment."metastatic breast cancer (mbc)kadcyla, as a single agent, is indicated for the treatment of patients with her2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either:• received prior therapy for metastatic disease, or• developed disease recurrence during or within six months of completing adjuvant therapy."

Israel - anglès - Ministry of Health

roche pharmaceuticals (israel) ltd - polatuzumab vedotin - powder for concentrate for solution for infusion - polatuzumab vedotin 140 mg/vial - polivy in combination with bendamustine and rituximab is indicated for the treatment of previously treated adult patients with diffuse large b-cell lymphoma who are not candidates for hematopoietic stem cell transplant.polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Cuba - espanyol - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

aurochem pharmaceuticals pvt. ltd., mumbai, india. - doxiciclina anhidra - tableta revestida - 100 mg